ERBB2 and cancer: Finally, a dose-ascending study of MM-111 in combination with multiple treatments studied 86 patients with advanced HER2-positive cancers and concluded a phase II dose of 20 mg/kg every week or 40 mg/kg every 3 weeks [52].